Positive immunoreactivity for HMB-45, a monoclonal antibody raised against a melanoma-associated antigen, is characteristic of AMLs and can be used to differentiate AMLs from other similar appearing lesions such as liposarcomas, lipomas, leiomyosarcomas or, leiomyomas [20, 25]. This evidence concerns the gene PMEL and leiomyosarcoma.